A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
NCT ID: NCT00596648
Last Updated: 2026-01-13
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
92 participants
Study Classification
INTERVENTIONAL
Study Start Date
2008-02-12
Study Completion Date
2012-08-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study consisted of a Phase 1 dose escalation/dose de-escalation portion to determine a safe and tolerable combination dose(s) of cabozantinib and erlotinib, and a Phase 2 Simon optimal 2-stage design portion with randomized assignment of subjects in an equal ratio to determine the objective response rate (ORR) of cabozantinib with or without erlotinib in subjects with non-small cell lung cancer (NSCLC) who have progressed after responding to treatment with erlotinib. The doses of cabozantinib used in this study were based on the salt weight, not the freebase weight.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
NCT01866410
Recurrent Non-Small Cell Lung Carcinoma
Stage IV Non-Small Cell Lung Cancer AJCC v7
COMPLETED
PHASE2
Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC
NCT00354549
Lung Cancer
COMPLETED
PHASE2
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT01708954
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7
ACTIVE_NOT_RECRUITING
PHASE2
Cabozantinib in Advanced Solid Malignancies
NCT01588821
Lung Cancer
Solid Tumor (Not Breast or Prostate Cancers)
COMPLETED
PHASE2
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
NCT03590054
Stage III Cutaneous Melanoma
Stage IV Cutaneous Melanoma
Locally Advanced Melanoma
+18 more
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Carcinoma, Non-Small-Cell Lung
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1 Arm
Escalating doses of XL184 + erlotinib
Group Type
EXPERIMENTAL
XL184
Intervention Type
DRUG
Capsules administered orally daily
erlotinib
Intervention Type
DRUG
Tablets administered orally daily.
Phase 2 Arm 1
XL184 + erlotinib (dose determined from Phase 1 portion of study)
Group Type
EXPERIMENTAL
XL184
Intervention Type
DRUG
Capsules administered orally daily
erlotinib
Intervention Type
DRUG
Tablets administered orally daily.
Phase 2 Arm 2
XL184 administered as a single agent
Group Type
EXPERIMENTAL
XL184
Intervention Type
DRUG
Capsules administered orally daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
XL184
Capsules administered orally daily
Intervention Type
DRUG
erlotinib
Tablets administered orally daily.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects had pathologically confirmed NSCLC and currently have Stage IIIb or IV NSCLC
* Subjects had failed treatment with erlotinib at 150 mg qd
* Subjects had tolerated erlotinib at the dose of the cohort in which they were enrolled (or at a higher dose) for at least 6 weeks (or for the duration of treatment if disease progression had occurred during treatment with erlotinib for less than 6 weeks)
* The subject was at least 18 years old
* The subject had an ECOG performance status of \< 2
* The subject had organ and marrow function as follows: - absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, bilirubin ≤ 1.5 times the upper limit of normal, serum creatinine ≤ 1.5 mg/dL or if serum creatinine \> 1.5 mg/dL calculated creatinine clearance ≥ 60 mL/min, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal, amylase and lipase \< 1.5 times the upper limit of normal
* Sexually active subjects had to agree to use medically accepted methods of contraception during the course of the study and for 3 months following discontinuation of study treatments (excluding women who are not of child bearing potential and men who have been sterilized)
* Female subjects of childbearing potential had to have a negative pregnancy test at enrollment. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to prior chemotherapy, antiestrogens, or ovarian suppression
* The subject had no other diagnosis of malignancy (unless non-melanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed ≥ 2 years previously, and currently with no evidence of disease)
* Subjects had pathologically confirmed NSCLC and currently have Stage IIIb or IV NSCLC
* Subjects had: Documented radiological PD, following a prior response, per investigator assessment, to monotherapy with erlotinib, OR; Documented radiological PD, per investigator assessment, following stable disease of at least 6 months on monotherapy with erlotinib
* Subjects who had received subsequent anti-cancer therapy after having progressed on erlotinib (as defined above) also had to have documented radiological PD per investigator assessment to their most recent anti-cancer therapy. If the most recent anti-cancer therapy was erlotinib after having previously progressed on erlotinib (as defined above) the subject also had to have documented radiological PD per investigator assessment to their most recent course of erlotinib
* Subjects had to have tolerated erlotinib at the maximal dose that would be administered in Phase 2 (or at a higher dose) for a minimum of 6 weeks
* Subjects had measurable disease per RECIST
* Subjects had to have 15 unstained consecutive slides of archival or fresh tumor tissue (from one tumor block, frozen tumor tissue, or a paraffin block) identified and designated for shipment to the sponsor if permitted by local regulations (including IRB \[Institutional Review Board\] policies). The eligibility of subjects with \< 15 unstained slides of available archival tissue was discussed with the sponsor
* The subject was at least 18 years old
* The subject had an ECOG performance status of \< 1
* The subject had organ and marrow function as follows: absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, bilirubin ≤ 1.5 times the upper limit of normal, serum creatinine ≤ 1.5 mg/dL or if serum creatinine \> 1.5 mg/dL calculated creatinine clearance ≥ 60 mL/min, ALT and AST ≤ 2.5 times the upper limit of normal, amylase and lipase \< 1.5 times the upper limit of normal
* Sexually active subjects had to agree to use medically accepted methods of contraception during the course of the study and for 3 months following discontinuation of study treatments (excluding women who are not of child bearing potential and men who have been sterilized)
* Female subjects of childbearing potential had to have a negative pregnancy test at enrollment. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to prior chemotherapy, antiestrogens, or ovarian suppression
* The subject had no other diagnosis of malignancy (unless non-melanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed ≥ 2 years previously, and currently with no evidence of disease)
* Subjects had failed treatment with erlotinib at 150 mg qd
* Subjects had tolerated erlotinib at the dose of the cohort in which they were enrolled (or at a higher dose) for at least 6 weeks (or for the duration of treatment if disease progression had occurred during treatment with erlotinib for less than 6 weeks)
* The subject was at least 18 years old
* The subject had an ECOG performance status of \< 2
* The subject had organ and marrow function as follows: - absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, bilirubin ≤ 1.5 times the upper limit of normal, serum creatinine ≤ 1.5 mg/dL or if serum creatinine \> 1.5 mg/dL calculated creatinine clearance ≥ 60 mL/min, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal, amylase and lipase \< 1.5 times the upper limit of normal
* Sexually active subjects had to agree to use medically accepted methods of contraception during the course of the study and for 3 months following discontinuation of study treatments (excluding women who are not of child bearing potential and men who have been sterilized)
* Female subjects of childbearing potential had to have a negative pregnancy test at enrollment. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to prior chemotherapy, antiestrogens, or ovarian suppression
* The subject had no other diagnosis of malignancy (unless non-melanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed ≥ 2 years previously, and currently with no evidence of disease)
* Subjects had pathologically confirmed NSCLC and currently have Stage IIIb or IV NSCLC
* Subjects had: Documented radiological PD, following a prior response, per investigator assessment, to monotherapy with erlotinib, OR; Documented radiological PD, per investigator assessment, following stable disease of at least 6 months on monotherapy with erlotinib
* Subjects who had received subsequent anti-cancer therapy after having progressed on erlotinib (as defined above) also had to have documented radiological PD per investigator assessment to their most recent anti-cancer therapy. If the most recent anti-cancer therapy was erlotinib after having previously progressed on erlotinib (as defined above) the subject also had to have documented radiological PD per investigator assessment to their most recent course of erlotinib
* Subjects had to have tolerated erlotinib at the maximal dose that would be administered in Phase 2 (or at a higher dose) for a minimum of 6 weeks
* Subjects had measurable disease per RECIST
* Subjects had to have 15 unstained consecutive slides of archival or fresh tumor tissue (from one tumor block, frozen tumor tissue, or a paraffin block) identified and designated for shipment to the sponsor if permitted by local regulations (including IRB \[Institutional Review Board\] policies). The eligibility of subjects with \< 15 unstained slides of available archival tissue was discussed with the sponsor
* The subject was at least 18 years old
* The subject had an ECOG performance status of \< 1
* The subject had organ and marrow function as follows: absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL, bilirubin ≤ 1.5 times the upper limit of normal, serum creatinine ≤ 1.5 mg/dL or if serum creatinine \> 1.5 mg/dL calculated creatinine clearance ≥ 60 mL/min, ALT and AST ≤ 2.5 times the upper limit of normal, amylase and lipase \< 1.5 times the upper limit of normal
* Sexually active subjects had to agree to use medically accepted methods of contraception during the course of the study and for 3 months following discontinuation of study treatments (excluding women who are not of child bearing potential and men who have been sterilized)
* Female subjects of childbearing potential had to have a negative pregnancy test at enrollment. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to prior chemotherapy, antiestrogens, or ovarian suppression
* The subject had no other diagnosis of malignancy (unless non-melanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed ≥ 2 years previously, and currently with no evidence of disease)
Exclusion Criteria
* The subject had received anti-cancer treatment (eg, chemotherapy, radiotherapy, cytokines, or hormones) within 4 weeks with exception of erlotinib (6 weeks for nitrosoureas or mitomycin C) before the first dose of study drug
* The subject had not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade ≤1 from clinically significant adverse events (AEs) due to antineoplastic agents, investigational drugs, or other medications that were administered prior to study enrollment
* The subject had symptomatic or uncontrolled brain metastases requiring current treatment, including steroids and anticonvulsants
* The subject had a history of clinically significant hematemesis or a recent history of hemoptysis of \> 0.5 teaspoon of red blood or other signs indicative of pulmonary hemorrhage
* The subject had the presence of cavitation, endobronchial lesion or a lesion abutting a major blood vessel
* The subject had serious intercurrent illness, such as uncontrolled hypertension (sustained blood pressure \[BP\] readings of \> 140 mmHg systolic or \> 90 mmHg diastolic not controlled with anti-hypertensive medication), unhealed wounds from recent surgery or clinically significant cardiac arrhythmias or a recent history of significant disease such as either symptomatic congestive heart failure or unstable angina pectoris within 3 months or myocardial infarction within 6 months before the first dose of study drug
* The subject was pregnant or breastfeeding
* The subject had an active infection requiring systemic treatment
* The subject had an allergy or hypersensitivity to components of either the cabozantinib or erlotinib formulations
* The subject was incapable of understanding and complying with the protocol or unable to provide informed consent
* The subject had received: Small molecule inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2)/ kinase insert domain receptor (KDR) at anytime, OR; An investigational anti-cancer agent within 4 weeks of the first dose of study drug, OR; Investigational small molecule inhibitors of EGFR at any time, OR; A small molecule inhibitor of epidermal growth factor (EGF)/EGFR at any time (with the exception of erlotinib and gefitinib), OR; Anti-cancer therapy, including radiation therapy, within 4 weeks of the first dose of study drug (with the exception of gefitinib and erlotinib), OR; Prior therapy with a c-Met inhibitor. Recent (within 3 months) radiation therapy to the thoracic cavity including brachytherapy, unless radiation therapy targeted only bone metastasis
* The subject had not recovered to NCI CTCAE v3.0 Grade ≤1 from clinically significant AEs due to antineoplastic agents, investigational drugs, or other medications that were administered prior to study enrollment
* The subject had symptomatic or uncontrolled brain metastases requiring current treatment, including steroids and anticonvulsants
* The subject had experienced clinically significant hematemesis or hemoptysis of \> 0.5 teaspoon of red blood within 3 months before the first dose of study treatment, or other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
* The subject had cavitating pulmonary lesion(s), known endobronchial disease or a pulmonary lesion abutting or encasing a major blood vessel
* The subject had serious intercurrent illness, such as uncontrolled hypertension (sustained BP readings of \> 140 mmHg systolic or \> 90 mmHg diastolic not controlled with anti hypertensive medication), unhealed wounds from recent surgery or clinically significant cardiac arrhythmias or a recent history of significant disease such as either symptomatic congestive heart failure or unstable angina pectoris within the past 3 months, myocardial infarction, stroke, or transient ischemic attack within the past 6 months
* The subject was pregnant or breastfeeding
* The subject had a clinically significant active infection requiring systemic treatment
* The subject had an allergy or hypersensitivity to components of either the cabozantinib or erlotinib formulations
* The subject was incapable of understanding and complying with the protocol or unable to provide informed consent
* The subject had a history of idiopathic pulmonary fibrosis or interstitial lung disease (ILD)
* The subject had not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade ≤1 from clinically significant adverse events (AEs) due to antineoplastic agents, investigational drugs, or other medications that were administered prior to study enrollment
* The subject had symptomatic or uncontrolled brain metastases requiring current treatment, including steroids and anticonvulsants
* The subject had a history of clinically significant hematemesis or a recent history of hemoptysis of \> 0.5 teaspoon of red blood or other signs indicative of pulmonary hemorrhage
* The subject had the presence of cavitation, endobronchial lesion or a lesion abutting a major blood vessel
* The subject had serious intercurrent illness, such as uncontrolled hypertension (sustained blood pressure \[BP\] readings of \> 140 mmHg systolic or \> 90 mmHg diastolic not controlled with anti-hypertensive medication), unhealed wounds from recent surgery or clinically significant cardiac arrhythmias or a recent history of significant disease such as either symptomatic congestive heart failure or unstable angina pectoris within 3 months or myocardial infarction within 6 months before the first dose of study drug
* The subject was pregnant or breastfeeding
* The subject had an active infection requiring systemic treatment
* The subject had an allergy or hypersensitivity to components of either the cabozantinib or erlotinib formulations
* The subject was incapable of understanding and complying with the protocol or unable to provide informed consent
* The subject had received: Small molecule inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2)/ kinase insert domain receptor (KDR) at anytime, OR; An investigational anti-cancer agent within 4 weeks of the first dose of study drug, OR; Investigational small molecule inhibitors of EGFR at any time, OR; A small molecule inhibitor of epidermal growth factor (EGF)/EGFR at any time (with the exception of erlotinib and gefitinib), OR; Anti-cancer therapy, including radiation therapy, within 4 weeks of the first dose of study drug (with the exception of gefitinib and erlotinib), OR; Prior therapy with a c-Met inhibitor. Recent (within 3 months) radiation therapy to the thoracic cavity including brachytherapy, unless radiation therapy targeted only bone metastasis
* The subject had not recovered to NCI CTCAE v3.0 Grade ≤1 from clinically significant AEs due to antineoplastic agents, investigational drugs, or other medications that were administered prior to study enrollment
* The subject had symptomatic or uncontrolled brain metastases requiring current treatment, including steroids and anticonvulsants
* The subject had experienced clinically significant hematemesis or hemoptysis of \> 0.5 teaspoon of red blood within 3 months before the first dose of study treatment, or other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
* The subject had cavitating pulmonary lesion(s), known endobronchial disease or a pulmonary lesion abutting or encasing a major blood vessel
* The subject had serious intercurrent illness, such as uncontrolled hypertension (sustained BP readings of \> 140 mmHg systolic or \> 90 mmHg diastolic not controlled with anti hypertensive medication), unhealed wounds from recent surgery or clinically significant cardiac arrhythmias or a recent history of significant disease such as either symptomatic congestive heart failure or unstable angina pectoris within the past 3 months, myocardial infarction, stroke, or transient ischemic attack within the past 6 months
* The subject was pregnant or breastfeeding
* The subject had a clinically significant active infection requiring systemic treatment
* The subject had an allergy or hypersensitivity to components of either the cabozantinib or erlotinib formulations
* The subject was incapable of understanding and complying with the protocol or unable to provide informed consent
* The subject had a history of idiopathic pulmonary fibrosis or interstitial lung disease (ILD)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Exelixis
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Exelixis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Katmai Oncology Group
Anchorage, Alaska, United States
Site Status
Stanford University Medical Center
Palo Alto, California, United States
Site Status
University of California, Davis
Sacramento, California, United States
Site Status
Yale University School of Medicine
New Haven, Connecticut, United States
Site Status
Georgetown University/Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
Site Status
University of Chicago Medical Center
Chicago, Illinois, United States
Site Status
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Site Status
Park Nicollet Institute
Saint Louis Park, Minnesota, United States
Site Status
Summit Medical Group
Berkeley Heights, New Jersey, United States
Site Status
Case Western Reserve University
Cleveland, Ohio, United States
Site Status
MD Anderson Cancer Center
Houston, Texas, United States
Site Status
Swedish Cancer Institute
Seattle, Washington, United States
Site Status
University of Washington/ Seattle Cancer Care Alliance
Seattle, Washington, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XL184-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
NCT00445848
COMPLETED
PHASE2
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
NCT05941897
ACTIVE_NOT_RECRUITING
PHASE2
Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
NCT02132598
TERMINATED
PHASE2
Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab
NCT00536640
COMPLETED
PHASE2
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02574078
COMPLETED
PHASE1/PHASE2
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
NCT00621049
COMPLETED
PHASE2
A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
NCT05132413
UNKNOWN
PHASE3
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
NCT02155465
COMPLETED
PHASE1/PHASE2
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
NCT05354700
UNKNOWN
PHASE2
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
NCT05751187
RECRUITING
PHASE2
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
NCT04189614
ACTIVE_NOT_RECRUITING
PHASE1
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
NCT03647488
COMPLETED
PHASE2
Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer
NCT00145418
TERMINATED
PHASE2
PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
NCT00548093
COMPLETED
PHASE2
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
NCT05467748
NOT_YET_RECRUITING
PHASE1/PHASE2
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT04475939
ACTIVE_NOT_RECRUITING
PHASE3
Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer
NCT00465907
TERMINATED
PHASE2
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
NCT00854308
COMPLETED
PHASE2
Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC
NCT00283244
COMPLETED
PHASE2
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
NCT01998919
COMPLETED
PHASE2
2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
NCT00835471
COMPLETED
PHASE2
Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer
NCT01350817
COMPLETED
PHASE2
First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial
NCT05648071
UNKNOWN
PHASE3
Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer
NCT00702182
COMPLETED
PHASE1
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00661193
COMPLETED
PHASE2